Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2015 (2015), Article ID 309602, 11 pages
http://dx.doi.org/10.1155/2015/309602
Review Article

Therapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies

1Regenerative Medicine, Mawson Institute, University of South Australia, Adelaide, SA 5001, Australia
2ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Mawson Institute, University of South Australia, Adelaide, SA 5001, Australia

Received 3 November 2014; Accepted 25 November 2014

Academic Editor: Haifeng Chen

Copyright © 2015 Christopher T. Turner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Maynard and G. Georgiou, “Antibody engineering,” Annual Review of Biomedical Engineering, vol. 2, no. 2000, pp. 339–376, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Boross and J. H. Leusen, “Mechanisms of action of CD20 antibodies,” American Journal of Cancer Research, vol. 2, no. 6, pp. 676–690, 2012. View at Google Scholar
  3. C. Chaudhury, S. Mehnaz, J. M. Robinson et al., “The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan,” The Journal of Experimental Medicine, vol. 197, no. 3, pp. 315–322, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Nelson, “Antibody fragments: hope and hype,” mAbs, vol. 2, no. 1, pp. 77–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Á. M. Cuesta, N. Sainz-Pastor, J. Bonet, B. Oliva, and L. Álvarez-Vallina, “Multivalent antibodies: when design surpasses evolution,” Trends in Biotechnology, vol. 28, no. 7, pp. 355–362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Iyer and V. J. Kadambi, “Antibody drug conjugates—trojan horses in the war on cancer,” Journal of Pharmacological and Toxicological Methods, vol. 64, no. 3, pp. 207–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. B. M. William and P. J. Bierman, “I-131 tositumomab,” Expert Opinion on Biological Therapy, vol. 10, no. 8, pp. 1271–1278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. E. Jackson, Z. Kopecki, D. H. Adams, and A. J. Cowin, “Flii neutralizing antibodies improve wound healing in porcine preclinical studies,” Wound Repair and Regeneration, vol. 20, no. 4, pp. 523–536, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Iannello and A. Ahmad, “Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies,” Cancer and Metastasis Reviews, vol. 24, no. 4, pp. 487–499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Zhuang, W. Xu, Y. Shen, and J. Li, “Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-hodgkin lymphoma and chronic lymphocytic leukemia,” Clinical Lymphoma, Myeloma & Leukemia, vol. 10, no. 5, pp. 347–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. G. Presta, “Engineering of therapeutic antibodies to minimize immunogenicity and optimize function,” Advanced Drug Delivery Reviews, vol. 58, no. 5-6, pp. 640–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Yang and A. Ambrogelly, “Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies,” Current Opinion in Biotechnology, vol. 30, pp. 225–229, 2014. View at Publisher · View at Google Scholar
  13. A. Patel, K. Cholkar, and A. K. Mitra, “Recent developments in protein and peptide parenteral delivery approaches,” Therapeutic Delivery, vol. 5, no. 3, pp. 337–365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Ismael, R. Hegg, S. Muehlbauer et al., “Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial,” The Lancet Oncology, vol. 13, no. 9, pp. 869–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. R. J. Keizer, A. D. R. Huitema, J. H. M. Schellens, and J. H. Beijnen, “Clinical pharmacokinetics of therapeutic monoclonal antibodies,” Clinical Pharmacokinetics, vol. 49, no. 8, pp. 493–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Kopecki, N. Ruzehaji, C. Turner et al., “Topically applied flightless i neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita,” Journal of Investigative Dermatology, vol. 133, no. 4, pp. 1008–1016, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Chames, M. van Regenmortel, E. Weiss, and D. Baty, “Therapeutic antibodies: successes, limitations and hopes for the future,” British Journal of Pharmacology, vol. 157, no. 2, pp. 220–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Vieira and K. Rajewsky, “The half-lives of serum immunoglobulins in adult mice,” European Journal of Immunology, vol. 18, no. 2, pp. 313–316, 1988. View at Publisher · View at Google Scholar · View at Scopus
  19. D. C. Roopenian and S. Akilesh, “FcRn: the neonatal Fc receptor comes of age,” Nature Reviews Immunology, vol. 7, no. 9, pp. 715–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Farajnia, V. Ahmadzadeh, A. Tanomand, K. Veisi, S. A. Khosroshahi, and L. Rahbarnia, “Development trends for generation of single-chain antibody fragments,” Immunopharmacology and Immunotoxicology, vol. 36, no. 5, pp. 297–308, 2014. View at Publisher · View at Google Scholar
  21. P. D. Senter, “Potent antibody drug conjugates for cancer therapy,” Current Opinion in Chemical Biology, vol. 13, no. 3, pp. 235–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Fujimori, D. G. Covell, J. E. Fletcher, and J. N. Weinstein, “A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier,” Journal of Nuclear Medicine, vol. 31, no. 7, pp. 1191–1198, 1990. View at Google Scholar · View at Scopus
  23. G. P. Adams, R. Schier, A. M. McCall et al., “High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules,” Cancer Research, vol. 61, no. 12, pp. 4750–4755, 2001. View at Google Scholar · View at Scopus
  24. R. Gniadecki, B. Bang, L. E. Bryld, L. Iversen, S. Lasthein, and L. Skov, “Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris,” British Journal of Dermatology, 2014. View at Publisher · View at Google Scholar
  25. G. Goldstein, J. Schindler, and H. Tsai, “A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants,” The New England Journal of Medicine, vol. 313, no. 6, pp. 337–342, 1985. View at Publisher · View at Google Scholar · View at Scopus
  26. F. M. Wagner, H. Reichenspurner, P. Uberfuhr et al., “How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?” The Journal of Heart and Lung Transplantation, vol. 13, no. 3, pp. 438–443, 1994. View at Google Scholar · View at Scopus
  27. P. B. Jensen, S. A. Birkeland, N. Rohr, A. Elbirk, and K. A. Jørgensen, “Development of anti-OKT3 antibodies after OKT3 treatment,” Scandinavian Journal of Urology and Nephrology, vol. 30, no. 3, pp. 227–230, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Roque-Navarro, C. Mateo, J. Lombardero et al., “Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method,” Hybridoma and Hybridomics, vol. 22, no. 4, pp. 245–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. K.-S. Kim, H.-J. Kim, B. W. Han, P.-K. Myung, and H. J. Hong, “Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization,” Biochemical and Biophysical Research Communications, vol. 396, no. 2, pp. 231–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. E. L. Sievers and P. D. Senter, “Antibody-drug conjugates in cancer therapy,” Annual Review of Medicine, vol. 64, pp. 15–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Lei, P. Liu, B. Chen et al., “Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy,” Journal of the American Chemical Society, vol. 132, no. 20, pp. 6906–6907, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. L. Macura, J. L. Steinbacher, M. B. MacPherson et al., “Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts,” BMC Cancer, vol. 13, article 400, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Sundarraj, R. Thangam, M. V. Sujitha, K. Vimala, and S. Kannan, “Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy,” Toxicology and Applied Pharmacology, vol. 275, no. 3, pp. 232–243, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Chen, H. Hong, Y. Zhang et al., “In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles,” ACS Nano, vol. 7, no. 10, pp. 9027–9039, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Chen, T. R. Nayak, S. Goel et al., “In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles,” Molecular Pharmaceutics, vol. 11, no. 11, pp. 4007–4014, 2014. View at Publisher · View at Google Scholar
  36. J. S. Andrew, E. J. Anglin, E. C. Wu et al., “Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide,” Advanced Functional Materials, vol. 20, no. 23, pp. 4168–4174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Secret, K. Smith, V. Dubljevic et al., “Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs,” Advanced Healthcare Materials, vol. 2, no. 5, pp. 718–727, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Gu, L. E. Ruff, Z. Qin, M. Corr, S. M. Hedrick, and M. J. Sailor, “Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody,” Advanced Materials, vol. 24, no. 29, pp. 3981–3987, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Lee, M.-Y. Lee, S. H. Bhang et al., “Hyaluronate-gold nanoparticle/Tocilizumab complex for the treatment of rheumatoid arthritis,” ACS Nano, vol. 8, no. 5, pp. 4790–4798, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Bisker, D. Yeheskely-Hayon, L. Minai, and D. Yelin, “Controlled release of Rituximab from gold nanoparticles for phototherapy of malignant cells,” Journal of Controlled Release, vol. 162, no. 2, pp. 303–309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. X. Shao, H. Zhang, J. R. Rajian et al., “125I-labeled gold nanorods for targeted imaging of inflammation,” ACS Nano, vol. 5, no. 11, pp. 8967–8973, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S. K. Cho, K. Emoto, L.-J. Su, X. Yang, T. W. Flaig, and W. Park, “Functionalized gold nanorods for thermal ablation treatment of bladder cancer,” Journal of Biomedical Nanotechnology, vol. 10, no. 7, pp. 1267–1276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Shen, K. Li, L. Cheng, Z. Liu, S.-T. Lee, and J. Liu, “Specific detection and simultaneously localized photothermal treatment of cancer cells using layer-by-layer assembled multifunctional nanoparticles,” ACS Applied Materials and Interfaces, vol. 6, no. 9, pp. 6443–6452, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Hong, K. Yang, Y. Zhang et al., “In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene,” ACS Nano, vol. 6, no. 3, pp. 2361–2370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. F. M. Kievit, Z. R. Stephen, O. Veiseh et al., “Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs,” ACS Nano, vol. 6, no. 3, pp. 2591–2601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Kost and R. Langer, “Responsive polymeric delivery systems,” Advanced Drug Delivery Reviews, vol. 46, no. 1–3, pp. 125–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Cao, B. Wang, Y. Wang, and D. Lou, “Dual drug release from core–shell nanoparticles with distinct release profiles,” Journal of Pharmaceutical Sciences, vol. 103, no. 10, pp. 3205–3216, 2014. View at Publisher · View at Google Scholar
  48. Y. Chang and L. Xiao, “Preparation and characterization of a novel drug delivery system: biodegradable nanoparticles in thermosensitive chitosan/gelatin blend hydrogels,” Journal of Macromolecular Science Part A: Pure and Applied Chemistry, vol. 47, no. 6, pp. 608–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Hou, J. Hu, H. Park, and M. Lee, “Chitosan-based nanoparticles as a sustained protein release carrier for tissue engineering applications,” Journal of Biomedical Materials Research—Part A, vol. 100, no. 4, pp. 939–947, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. V. E. Santo, A. R. C. Duarte, M. E. Gomes, J. F. Mano, and R. L. Reis, “Hybrid 3D structure of poly(d,l-lactic acid) loaded with chitosan/chondroitin sulfate nanoparticles to be used as carriers for biomacromolecules in tissue engineering,” Journal of Supercritical Fluids, vol. 54, no. 3, pp. 320–327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Valo, S. Arola, P. Laaksonen et al., “Drug release from nanoparticles embedded in four different nanofibrillar cellulose aerogels,” European Journal of Pharmaceutical Sciences, vol. 50, no. 1, pp. 69–77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Z. Volpato, J. Almodóvar, K. Erickson, K. C. Popat, C. Migliaresi, and M. J. Kipper, “Preservation of FGF-2 bioactivity using heparin-based nanoparticles, and their delivery from electrospun chitosan fibers,” Acta Biomaterialia, vol. 8, no. 4, pp. 1551–1559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. K. Yandrapu, A. K. Upadhyay, J. M. Petrash, and U. B. Kompella, “Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab,” Molecular Pharmaceutics, vol. 10, no. 12, pp. 4676–4686, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. M. R. Green, G. M. Manikhas, S. Orlov et al., “Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer,” Annals of Oncology, vol. 17, no. 8, pp. 1263–1268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Andreopoulou, D. Gaiotti, E. Kim et al., “Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer,” Annals of Oncology, vol. 18, no. 4, pp. 716–721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Yang, S. Gai, and J. Lin, “Functionalized mesoporous silica materials for controlled drug delivery,” Chemical Society Reviews, vol. 41, no. 9, pp. 3679–3698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. E. J. Anglin, L. Cheng, W. R. Freeman, and M. J. Sailor, “Porous silicon in drug delivery devices and materials,” Advanced Drug Delivery Reviews, vol. 60, no. 11, pp. 1266–1277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. S. J. P. McInnes and N. H. Voelcker, “Silicon-polymer hybrid materials for drug delivery,” Future Medicinal Chemistry, vol. 1, no. 6, pp. 1051–1074, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Fine, A. Grattoni, R. Goodall et al., “Silicon micro- and nanofabrication for medicine,” Advanced Healthcare Materials, vol. 2, no. 5, pp. 632–666, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. A. M. A. Elhissi, W. Ahmed, I. U. Hassan, V. R. Dhanak, and A. D'Emanuele, “Carbon nanotubes in cancer therapy and drug delivery,” Journal of Drug Delivery, vol. 2012, Article ID 837327, 10 pages, 2012. View at Publisher · View at Google Scholar
  61. D. Kumar, N. Saini, N. Jain, R. Sareen, and V. Pandit, “Gold nanoparticles: an era in bionanotechnology,” Expert Opinion on Drug Delivery, vol. 10, no. 3, pp. 397–409, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Bose, S. Tarafder, J. Edgington, and A. Bandyopadhyay, “Calcium phosphate ceramics in drug delivery,” JOM, vol. 63, no. 4, pp. 93–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. I. I. Slowing, B. G. Trewyn, and V. S.-Y. Lin, “Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins,” Journal of the American Chemical Society, vol. 129, no. 28, pp. 8845–8849, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. Z. Deng, Z. Zhen, X. Hu, S. Wu, Z. Xu, and P. K. Chu, “Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy,” Biomaterials, vol. 32, no. 21, pp. 4976–4986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. N. W. S. Kam and H. Dai, “Carbon nanotubes as intracellular protein transporters: generality and biological functionality,” Journal of the American Chemical Society, vol. 127, no. 16, pp. 6021–6026, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. P. M. Tiwari, E. Eroglu, S. S. Bawage et al., “Enhanced intracellular translocation and biodistribution of gold nanoparticles functionalized with a cell-penetrating peptide (VG-21) from vesicular stomatitis virus,” Biomaterials, vol. 35, no. 35, pp. 9484–9494, 2014. View at Publisher · View at Google Scholar
  67. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,” Journal of Controlled Release, vol. 65, no. 1-2, pp. 271–284, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Greish, “Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines,” Journal of Drug Targeting, vol. 15, no. 7-8, pp. 457–464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. R. H. Weisbart, J. F. Gera, G. Chan et al., “A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets,” Molecular Cancer Therapeutics, vol. 11, no. 10, pp. 2169–2173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. C.-Y. Lai, B. G. Trewyn, D. M. Jeftinija et al., “A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules,” Journal of the American Chemical Society, vol. 125, no. 15, pp. 4451–4459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Radin, S. Falaize, M. H. Lee, and P. Ducheyne, “In vitro bioactivity and degradation behavior of silica xerogels intended as controlled release materials,” Biomaterials, vol. 23, no. 15, pp. 3113–3122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. C. T. Kresge, M. E. Leonowicz, W. J. Roth, J. C. Vartuli, and J. S. Beck, “Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism,” Nature, vol. 359, no. 6397, pp. 710–712, 1992. View at Google Scholar · View at Scopus
  73. M. Vallet-Regí, F. Balas, and D. Arcos, “Mesoporous materials for drug delivery,” Angewandte Chemie, vol. 46, no. 40, pp. 7548–7558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. H.-S. Shin, Y.-K. Hwang, and S. Huh, “Facile preparation of ultra-large pore mesoporous silica nanoparticles and their application to the encapsulation of large guest molecules,” ACS Applied Materials and Interfaces, vol. 6, no. 3, pp. 1740–1746, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Park, H. Kim, S. Kim, and C. Kim, “Enzyme responsive nanocontainers with cyclodextrin gatekeepers and synergistic effects in release of guests,” Journal of the American Chemical Society, vol. 131, no. 46, pp. 16614–16615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Pourjavadi and Z. M. Tehrani, “Mesoporous silica nanoparticles (MCM-41) coated PEGylated chitosan as a pH-responsive nanocarrier for triggered release of erythromycin,” International Journal of Polymeric Materials and Polymeric Biomaterials, vol. 63, no. 13, pp. 692–697, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Canham, Properties of Porous Silicon, Short Run Press, London, UK, 2006.
  78. S. J. P. McInnes and N. H. Voelcker, “Porous silicon–polymer composites for cell culture and tissue engineering applications,” in Porous Silicon for Biomedical Applications, Woodhead, Cambridge, UK, 2014. View at Google Scholar
  79. J. Schmeltzer and J. Buriak, Recent Developments in the Chemistry and Chemical Applications of Porous Silicon, Wiley-VCH, Weinheim, Germany, 2004.
  80. M. P. Stewart and J. M. Buriak, “Chemical and biological applications of porous silicon technology,” Advanced Materials, vol. 12, no. 12, pp. 859–869, 2000. View at Google Scholar · View at Scopus
  81. W. H. Green, S. Létant, and M. J. Sailor, “Electrochemical formation and modification of nanocrystalline porous silicon,” in Electrochemistry of Nanomaterials, G. Hodes, Ed., pp. 141–167, Wiley, 2001. View at Google Scholar
  82. M. P. Stewart and J. M. Buriak, “New approaches toward the formation of silicon-carbon bonds on porous silicon,” Comments on Inorganic Chemistry, vol. 23, no. 3, pp. 179–203, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Salonen and V.-P. Lehto, “Fabrication and chemical surface modification of mesoporous silicon for biomedical applications,” Chemical Engineering Journal, vol. 137, no. 1, pp. 162–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Jain, S. R. Singh, and S. Pillai, “Toxicity issues related to biomedical applications of carbon nanotubes,” Journal of Nanomedicine & Nanotechnology, vol. 3, no. 5, 2012. View at Google Scholar
  85. C. Salvador-Morales, E. Flahaut, E. Sim, J. Sloan, M. L. H. Green, and R. B. Sim, “Complement activation and protein adsorption by carbon nanotubes,” Molecular Immunology, vol. 43, no. 3, pp. 193–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. N. W. S. Kam, T. C. Jessop, P. A. Wender, and H. Dai, “Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells,” Journal of the American Chemical Society, vol. 126, no. 22, pp. 6850–6851, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Josephson, “Magnetic nanoparticles for MR imaging,” in BioMEMS and Biomedical Nanotechnology, M. Ferrari, Ed., pp. 227–237, Springer, Boston, Mass, USA, 2006. View at Publisher · View at Google Scholar